KRAS and non-small cell lung carcinoma: The randomized, phase III CodeBreak 200 trial (NCT04303780), comparing sotorasib WITH docetaxel in advanced NSCLC patients with KRAS G12C mutation who have progressed after platinum-based doublet chemotherapy and checkpoint inhibitor, is currently recruiting [35].